Gainey McKenna & Egleston Announces A Class Action Lawsuit

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Pilgrim’s Pride Corporation (PPC)

NEW YORK, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Pilgrim’s Pride Corporation (“Pilgrim’s Pride” or the “Company”) (Nasdaq: PPC ) in the United States District Court for the District of Colorado on behalf of purchasers of common stock of Pilgrim’s Pride between February 21, 2014 and October 6, 2016, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”).

According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that:  (i) Pilgrim’s Pride systematically colluded with several of its industry peers to fix prices in the market for broiler chickens (i.e., chickens raised specifically for meat production); (ii) the foregoing conduct constituted a violation of federal antitrust laws; (iii) consequently, Pilgrim’s Pride’s revenues during the class period were the result of illegal conduct; and (iv) as a result of the foregoing, Pilgrim’s Pride’s public statements were materially false and misleading at all relevant times.

On September 2, 2016, food distributor Maplevale Farms, Inc. filed an antitrust lawsuit against Pilgrim’s Pride and other poultry producers, including Tyson Foods, Inc. (“Tyson”), alleging that Pilgrim’s Pride and the other companies named in the complaint had conspired since 2008 to manipulate the prices of broiler chickens.  Additionally, on October 7, 2016, Pivotal Research downgraded Tyson from “Hold” to “Sell.”  Explaining the downgrade, analyst Timothy Ramey directed investors’ attention to the allegations of price manipulation by Pilgrim’s Pride, Tyson, and their industry peers and described the lawsuit as “powerfully convincing.”

On this news, the Company’s share price fell from $21.11 per share on October 6, 2016 to a closing price of $20.16 on October 7, 2016—a $0.95 or a 4.5% drop.

If you wish to serve as lead plaintiff, you must move the Court no later than December 19, 2016 .   A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com .

Please visit our website at http://www.gme-law.com for more information about the firm.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 70

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
PharmaBlock Forum: Strategic CMC Moves Crucial for Biotech

Updated Category News Views 44

CMC Strategies: The Unsung Hero in Biotech Development Ah, the world of biotech, where one day you're a hero in the lab, and the next you're scrambling to make sense of chemistry, manufacturing, and controls (CMC). It's high time folks started realizing that CMC isn't just procedural drudgery—it's the backbone of making a promising drug go global. That's what the...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 201

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 347

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 97

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 513

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Delta Marks 19 Years at COP With Bold New Initiatives

Updated Category News Views 0

Delta's Commitment to Global Sustainability Delta's name pops up yet again at the United Nations Climate Change Conference (COP31) in Antalya, Turkey, marking the company's 19th consecutive year of participation. They're mounting efforts to hit that "35×35" target, aiming for 35% electrification by 2035. This isn't just fluff and rhetoric—it’s Delta taking the lead...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Postpones Asia Cruise Ship Launch Amid Challenges

Updated Category News Views 232

Disney Delays Launch of Its First Asia Cruise Ship Walt Disney Co. (NYSE: DIS) has announced a three-month delay in the inaugural voyage of its first Asia-based cruise ship, the Disney Adventure. Originally set to embark from Singapore on December 15, the new launch date is now March 10, 2026, due to unexpected setbacks in the shipbuilding process. Challenges in...

Continue Reading
Promising Outcomes from ASPIRO Phase 1/2a Trial for Parkinson's

Updated Category News Views 159

Promising Results from Aspen Neuroscience's Clinical Study Aspen Neuroscience has recently shared encouraging insights from the ASPIRO Phase 1/2a clinical trial, focusing on their innovative cell therapy, ANPD001, aimed at treating Parkinson's Disease. This investigational approach leverages autologous dopaminergic neuronal precursor cells (DANPC) that hold the potential...

Continue Reading
Exploring Honeywell Intl's Options Trends and Market Analysis

Updated Category News Views 213

Understanding Honeywell Intl's Current Options Landscape The dynamic environment of finance recently showcased an intriguing shift with notable bearish movements concerning Honeywell Intl. The latest analysis of options trading data for Honeywell Intl (HON) has spotlighted a total of 10 unique trades that have piqued interest among traders. In an examination of the...

Continue Reading
Transforming Business with Google Agentspace and Premier Cloud

Updated Category News Views 217

Transforming Business with Google Agentspace and Premier Cloud Premier Cloud has been recognized as a launch partner for Google Agentspace, Google's innovative new AI platform that aims to revolutionize enterprise search and productivity. This partnership is a significant milestone for Premier Cloud, a prominent Google Cloud Premier Partner, renowned for its expertise in...

Continue Reading
Transforming Biotechnology: A New Era for Advanced Therapies

Updated Category News Views 156

Innovative Biomanufacturing Comes to Saudi Arabia At the forefront of a new biotechnology initiative, a strategic partnership has emerged between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC, unveiling a state-of-the-art Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. This exciting development represents a...

Continue Reading